Protein kinases as drug development targets for heart disease therapy

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2111-2145

  Dhalla, Naranjan S ^a   Müller, Alison L ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Mitogen activated protein kinases; Phosphoinositide 3 kinase; Protein kinase A; Protein kinase C

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANGIOTENSIN II; BREVISCAPINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; KT 5720; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE C ALPHA INHIBITOR; PROTEIN KINASE C BETA INHIBITOR; RO 318110; RUBOXISTAURIN; UNCLASSIFIED DRUG; WORTMANNIN;

CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77955690900     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072111     Document Type: Review

References (246)

1. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumourpromotion. Nature 1984, 308, 693-698.
2. Wood, J. S.; Yan, X.; Mendelow, M.; Corbin, J. D.; Francis, S. H.; Lawrence, D. S. Precisionsubstrate targeting of protein kinases. The cGMP- and cAMP-dependent protein kinases. J. Biol.Chem. 1996, 271, 174-179.
3. Dhalla, N. S.; Wang, J. Role of protein kinase C and protein kinase A in heart function in healthand disease. Exp. Clin. Cardiol. 1999, 4, 7-14.
4. Feuerstein, G. Z.; Young, P. R. Apoptosis in cardiac diseases: Stress- and mitogen-activatedsignaling pathways. Cardiovasc. Res. 2000, 45, 560-569.
5. Sugden, P. H.; Bogoyevitch, M. A. Intracellular signaling through protein kinases in the heart.Cardiovasc. Res. 1995, 30, 478-492.
6. Sadoshima, J.; Qiu, Z.; Morgan, J. P.; Izumo, S. Angiotensin II and other hypertrophic stimulimediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated proteinkinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca2+-dependent signaling.Circ. Res. 1995, 76, 1-15.
7. Kemp, B. E.; Bylund, D. B.; Huang, T. S.; Krebs, E. G. Substrate specificity of the cyclic AMPdependentprotein kinase. Proc. Natl. Acad. Sci. USA 1975, 72, 3448-3452.
8. Taylor, S. S.; Buechler, J. A.; Yonemoto, W. cAMP-dependent protein kinase: Framework for adiverse family of regulatory enzymes. Annu. Rev. Biochem. 1990, 59, 971-1005.
9. Opie, L. H. Receptors and signal transduction. In The Heart, Physiology and Metabolism; Opie, L. H., ed.; Raven Press: New York, NY, USA, 1991; pp. 147-175.
10. Barefield, D.; Sadayappan, S. Phosphorylation and function of cardiac myosin binding protein-Cin health and disease. J. Mol. Cell. Cardiol. 2010, 48, 866-875.
11. Baryshnikova, O. K.; Li, M. X.; Sykes, B. D. Modulation of cardiac troponin C function by thecardiac-specific N-terminus of troponin I: Influence of PKA phosphorylation and involvement incardiomyopathies. J. Mol. Biol. 2008, 375, 735-751.
12. Jones, P. P.; Meng, X.; Xiao, B.; Cai, S.; Bolstad, J.; Wagenknecht, T.; Liu, Z.; Chen, S. R.Localization of PKA phosphorylation site, Ser(2030), in the three-dimensional structure ofcardiac ryanodine receptor. Biochem. J. 2008, 410, 261-270.
13. Li, J.; Bigelow, D. J.; Squier, T. C. Conformational changes within the cytosolic portion ofphospholamban upon release of Ca-ATPase inhibition. Biochemistry 2004, 43, 3870-3879.
14. Wolff, M. R.; Buck, S. H.; Stoker, S. W.; Greaser, M. L.; Mentzer, R. M. Myofibrillar calciumsensitivity of isometric tension is increased in human dilated cardiomyopathies: Role of alteredbeta-adrenergically mediated protein phosphorylation. J. Clin. Invest. 1996, 98, 167-176.
15. Bogoyevitch, M. A.; Fuller, S. J.; Sugden, P. H. cAMP and protein synthesis in isolated adult ratheart preparations. Am. J. Physiol. Cell. Physiol. 1993, 265, C1247-C1257.
16. Bohm, M.; Reiger, B.; Schwinger, R. H.; Erdmann, E. cAMP concentrations, cAMP dependentprotein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc. Res. 1994, 28, 1713-1719.
17. Haase, H.; Karczewski, P.; Beckert, R.; Krause, E. G. Phosphorylation of the L-type calciumchannel beta subunit is involved in beta-adrenergic signal transduction in canine myocardium.FEBS Lett. 1993, 335, 217-222.
18. Perets, T.; Blumenstein, Y.; Shistik, E.; Lotan, I.; Dascal, N. A potential site of functionalmodulation by protein kinase A in the cardiac Ca2+ channel alpha 1C subunit. FEBS Lett. 1996,384, 189-192.
19. Milano, C. A.; Allen, L. F.; Rockman, H. A.; Dolber, P. C.; McMinn, T. R.; Chien, K. R.;Johnson, T. D.; Bond, R. A.; Lefkowitz, R. J. Enhanced myocardial function in transgenic miceoverexpressing the beta 2-adrenergic receptor. Science 1994, 264, 582-586.
20. Goldspink, P. H.; Russell, B. The cAMP response element binding protein is expressed andphosphorylated in cardiac myocytes. Circ. Res. 1994, 74, 1042-1049.
21. Phrommintikul, A.; Chattipakorn, N. Roles of cardiac ryanodine receptor in heart failure andsudden cardiac death. Int. J. Cardiol. 2006, 112, 142-152.
22. Mattiazzi, A.; Hove-Madsen, L.; Bers, D. M. Protein kinase inhibitors reduce SR Ca transport inpermeabilized cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 1994, 267, H812-H820.
23. Sichelschmidt, O. J.; Hahnefeld, C.; Hohlfeld, T.; Herberg, F. W.; Schror, K. Trapidil protectsischemic hearts from reperfusion injury by stimulating PKAII activity. Cardiovasc. Res. 2003,58, 602-610.
24. Schmitt, J. P.; Ahmad, F.; Lorenz, K.; Hein, L.; Schulz, S.; Asahi, M.; Maclennan, D. H.;Seidman, C. E.Seidman, J. G.; Lohse, M. J. Alterations of phospholamban function can exhibitcardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.Circulation 2009, 119, 436-444.
25. Xiao, B.; Zhong, G.; Obayashi, M.; Yang, D.; Chen, K.; Walsh, M. P.; Shimoni, Y.; Cheng, H.;Ter Keurs, H.; Chen, S. R. Ser-2030, but not Ser-2808, is the major phosphorylation site incardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergicstimulation in normal and failing hearts. Biochem. J. 2006, 396, 7-16.
26. Morimoto, S. J. O. U.; Kawai, M.; Hoshina, T.; Kusakari, Y.; Komukai, K.; Sasaki, H.; Hongo, K.; Kurihara, S. Protein kinase A-dependent phosphorylation of ryanodine receptors increasesCa2+ leak in mouse heart. Biochem. Biophys. Res. Commun. 2009, 390, 87-92
27. Pogwizd, S. M.; Bers, D. M. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc. Med. 2004, 14, 61-66.
28. Zakhary, D. R.; Moravec, C. S.; Bond, M. Regulation of PKA binding to AKAPs in the heart:alterations in human heart failure. Circulation 2000, 101, 1459-1464.
29. Zakhary, D. R.; Moravec, C. S.; Stewart, R. W.; Bond, M. Protein kinase A (PKA)-dependenttroponin-I phosphorylation and PKA regulatory subunits are decreased in human dilatedcardiomyopathy. Circulation 1999, 99, 505-510.
30. Piddo, A. M.; Sanchez, M. I.; Sapag-Hagar, M.; Corbalan, R.; Foncea, R.; Ebensperger, R.;Godoy, I.; Melendez, J.; Jalil, J. E.; Lavandero, S. Cyclic AMP-dependent protein kinase andmechanical heart function in ventricular hypertrophy induced by pressure overload or secondaryto myocardial infarction. J. Mol. Cell. Cardiol. 1996, 28, 1073-1083.
31. Dong, W. J.; Jayasundar, J. J.; An, J.; Xing, J.; Cheung, H. C. Effects of PKA phosphorylation ofcardiac troponin I and strong crossbridge on conformational transitions of the N-domain ofcardiac troponin C in regulated thin filaments. Biochemistry 2007, 46, 9752-9761.
32. Tong, C. W.; Stelzer, J. E.; Greaser, M. L.; Powers, P. A.; Moss, R. L. Acceleration ofcrossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein Cmodulates cardiac function. Circ. Res. 2008, 103, 974-982.
33. El-Armouche, A.; Boknik, P.; Eschenhagen, T.; Carrier, L.; Knaut, M.; Ravens, U.; Dobrev, D.Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation2006, 114, 670-680.
34. Jacques, A. M.; Copeland, O.; Messer, A. E.; Gallon, C. E.King, K.; McKenna, W. J.; Tsang, V.T.; Marston, S. B. Myosin binding protein C phosphorylation in normal, hypertrophic and failinghuman heart muscle. J. Mol. Cell. Cardiol. 2008, 45, 209-216.
35. van Dijk, S. J.; Dooijes, D.; dos Remedios, C.; Michels, M.; Lamers, J. M.; Winegrad, S.;Schlossarek, S.; Carrier, L.; ten Cate, F. J.; Stienen, G. J.; van der Velden, J. Cardiac myosinbindingprotein C mutations and hypertrophic cardiomyopathy: Haploinsufficiency, derangedphosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119, 1473-1483.
36. Ray, K. P.; England, P. J. Phosphorylation of the inhibitory subunit of troponin and its effect onthe calcium dependence of cardiac myofibril adenosine triphosphatase. FEBS Lett. 1976, 70,11-16.
37. Holroyde, M. J.; Potter, J. D.; Solaro, R. J. The calcium binding properties of phosphorylated andunphosphorylated cardiac and skeletal myosins. J. Biol. Chem. 1979, 254, 6478-6482.
38. Kentish, J. C.; McCloskey, D. T.; Layland, J.; Palmer, S.; Leiden, J. M.; Martin, A. F.; Solaro, R.J. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cyclekinetics in mouse ventricular muscle. Circ. Res. 2001, 88, 1059-1065.
39. Herron, T. J.; Korte, F. S.; McDonald, K. S. Power output is increased after phosphorylation ofmyofibrillar proteins in rat skinned cardiac myocytes. Circ. Res. 2001, 89, 1184-1190.
40. VanBuren, P.; Okada, Y. Thin filament remodeling in failing myocardium. Heart Fail. Rev.2005, 10, 199-209.
41. Makaula, S.; Lochner, A.; Genade, S.; Sack, M. N.; Awan, M. M.; Opie, L. H. H-89, a nonspecificinhibitor of protein kinase A, promotes post-ischemic cardiac contractile recovery andreduces infarct size. J. Cardiovasc. Pharmacol. 2005, 45, 341-347.
42. Oddis, C. V.; Simmons, R. L.; Hattler, B. G.; Finkel, M. S. Protein kinase A activation isrequired for IL-1-induced nitric oxide production by cardiac myocytes. Am. J. Physiol. Cell.Physiol. 1996, 271, C429-434.
43. Zhang, X. H.; Li, G. R.; Bourreau, J. P. The effect of adrenomedullin on the L-type calciumcurrent in myocytes from septic shock rats: signaling pathway. Am. J. Physiol. Heart Circ.Physiol. 2007, 293, H2888-2893.
44. Fontes-Sousa, A. P.; Pires, A. L.; Carneiro, C. S.; Bras-Silva, C.; Leite-Moreira, A. F. Effects ofadrenomedullin on systolic and diastolic myocardial function. Peptides 2009, 30, 796-802.
45. Ishimitsu, T.; Nishikimi, T.; Saito, Y.; Kitamura, K.; Eto, T.; Kangawa, K.; Matsuo, H.; Omae, T.; Matsuoka, H. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, inpatients with hypertension and renal failure. J. Clin. Invest. 1994, 94, 2158-2161.
46. Nishikimi, T.; Saito, Y.; Kitamura, K.; Ishimitsu, T.; Eto, T.; Kangawa, K.; Matsuo, H.; Omae, T.; Matsuoka, H. Increased plasma levels of adrenomedullin in patients with heart failure. J. Am.Coll. Cardiol. 1995, 26, 1424-1431.
47. Jougasaki, M.; Wei, C. M.; McKinley, L. J.; Burnett, J. C., Jr. Elevation of circulating andventricular adrenomedullin in human congestive heart failure. Circulation 1995, 92, 286-289.
48. Yoshitomi, Y.; Nishikimi, T.; Kojima, S.; Kuramochi, M.; Takishita, S.; Matsuoka, H.; Miyata, A.; Matsuo, H.; Kangawa, K. Plasma levels of adrenomedullin in patients with acute myocardialinfarction. Clin. Sci. 1998, 94, 135-139.
49. Nishida, H.; Sato, T.; Miyazaki, M.; Nakaya, H. Infarct size limitation by adrenomedullin:Protein kinase A but not PI3-kinase is linked to mitochondrial KCa channels. Cardiovasc. Res. 2008, 77, 398-405.
50. Mery, P. F.; Pavoine, C.; Belhassen, L.; Pecker, F.; Fischmeister, R. Nitric oxide regulatescardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterasesthrough guanylyl cyclase activation. J. Biol. Chem. 1993, 268, 26286-26295.
51. Shah, A. M.; Spurgeon, H. A.; Sollott, S. J.; Talo, A.; Lakatta, E. G. 8-bromo-cGMP reduces themyofilament response to Ca2+ in intact cardiac myocytes. Circ. Res. 1994, 74, 970-978.
52. Wahler, G. M.; Dollinger, S. J. Nitric oxide donor SIN-1 inhibits mammalian cardiac calciumcurrent through cGMP-dependent protein kinase. Am. J. Physiol. Cell. Physiol. 1995, 268,45-54.
53. Olson, R. E. Myocardial metabolism in congestive heart failure. J. Chronic Dis. 1959, 9,442-464.
54. Weber, K. T.; Brilla, C. G. Pathological hypertrophy and cardiac interstitium. Fibrosis and reninangiotensin-aldosterone system. Circulation 1991, 83, 1849-1865.
55. Saini, H. K.; Xu, Y. J.; Zhang, M.; Liu, P. P.; Kirshenbaum, L. A.; Dhalla, N. S. Role of tumournecrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart. Exp. Clin. Cardiol. 2005, 10, 213-222.
56. Murray, P. A.; Baig, H.; Fishbein, M. C.; Vatner, S. F. Effects of experimental right ventricularhypertrophy on myocardial blood flow in conscious dogs. J. Clin. Invest. 1979, 64, 421-427.
57. Yu, Q. J.; Si, R.; Zhou, N.; Zhang, H. F.; Guo, W. Y.; Wang, H. C.; Gao, F. Insulin inhibits betaadrenergicaction in ischemic/reperfused heart: A novel mechanism of insulin incardioprotection. Apoptosis 2008, 13, 305-317.
58. Asai, M.; Tsukamoto, O.; Minamino, T.; Asanuma, H.; Fujita, M.; Asano, Y.; Takahama, H.;Sasaki, H.; Higo, S.; Asakura, M.; Takashima, S.; Hori, M.; Kitakaze, M. PKA rapidly enhancesproteasome assembly and activity in in vivo canine hearts. J. Mol. Cell. Cardiol. 2009, 46,452-462.
59. Freude, B.; Masters, T. N.; Robicsek, F.; Fokin, A.; Kostin, S.; Zimmermann, R.; Ullmann, C.;Lorenz-Meyer, S.; Schaper, J. Apoptosis is initiated by myocardial ischemia and executed duringreperfusion. J. Mol. Cell. Cardiol. 2000, 32, 197-208.
60. Scarabelli, T.; Stephanou, A.; Rayment, N.; Pasini, E.; Comini, L.; Curello, S.; Ferrari, R.;Knight, R.; Latchman, D. Apoptosis of endothelial cells precedes myocyte cell apoptosis inischemia/reperfusion injury. Circulation 2001, 104, 253-256.
61. Gottlieb, R. A.; Burleson, K. O.; Kloner, R. A.; Babior, B. M.; Engler, R. L. Reperfusion injuryinduces apoptosis in rabbit cardiomyocytes. J. Clin. Invest. 1994, 94, 1621-1628.
62. Kajstura, J.; Cheng, W.; Reiss, K.; Clark, W. A.; Sonnenblick, E. H.; Krajewski, S.; Reed, J. C.;Olivetti, G.; Anversa, P. Apoptotic and necrotic myocyte cell deaths are independentcontributing variables of infarct size in rats. Lab. Invest. 1996, 74, 86-107.
63. Guerra, S.; Leri, A.; Wang, X.; Finato, N.; Di Loreto, C.; Beltrami, C. A.; Kajstura, J.; Anversa, P. Myocyte death in the failing human heart is gender dependent. Circ. Res. 1999, 85, 856-866.
64. Olivetti, G.; Abbi, R.; Quaini, F.; Kajstura, J.; Cheng, W.; Nitahara, J. A.; Quaini, E.; di Loreto, C.; Beltrami, C. A.; Krajewski, S.; Reed, J. C.; Anversa, P. Apoptosis in the failing human heart.N. Engl. J. Med. 1997, 336, 1131-1141.
65. Granata, R.; Trovato, L.; Gallo, M. P.; Destefanis, S.; Settanni, F.; Scarlatti, F.; Brero, A.;Ramella, R.; Volante, M.; Isgaard, J.; Levi, R.; Papotti, M.; Alloatti, G.; Ghigo, E. Growthhormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects againstischaemia-reperfusion injury in rat heart. Cardiovasc. Res. 2009, 83, 303-312.
66. Kwak, H. J.; Park, K. M.; Choi, H. E.; Chung, K. S.; Lim, H. J.; Park, H. Y. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA andEpac dual pathways. Cell. Signal. 2008, 20, 803-814.
67. Robinet, A.; Hoizey, G.; Millart, H. PI 3-kinase, protein kinase C, and protein kinase A areinvolved in the trigger phase of beta1-adrenergic preconditioning. Cardiovasc. Res. 2005, 66,530-542.
68. Chae, H. J.; Chae, S. W.; Kim, H. R. Cyclic adenosine monophosphate inhibits nitric oxideinducedapoptosis of cardiac muscle cells in a c-Jun N-terminal kinase-dependent manner. Immunopharmacol. Immunotoxicol. 2004, 26, 249-263.
69. Prabu, S. K.; Anandatheerthavarada, H. K.; Raza, H.; Srinivasan, S.; Spear, J. F.; Avadhani, N.G. Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function andaugments hypoxia and myocardial ischemia-related injury. J. Biol. Chem. 2006, 281, 2061-2070.
70. Tombes, R. M.; Faison, M. O.; Turbeville, J. M. Organization and evolution of multifunctionalCa(2+)/CaM-dependent protein kinase genes. Gene 2003, 322, 17-31.
71. Hudmon, A.; Schulman, H. Neuronal Ca2+/calmodulin-dependent protein kinase II: The role ofstructure and autoregulation in cellular function. Annu. Rev. Biochem. 2002, 71, 473-510.
72. Hudmon, A.; Schulman, H. Structure-function of the multifunctional Ca2+/calmodulin-dependentprotein kinase II. Biochem. J. 2002, 364, 593-611
73. De Koninck, P.; Schulman, H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations.Science 1998, 279, 227-230.
74. Lantsman, K.; Tombes, R. M. CaMK-II oligomerization potential determined using CFP/YFPFRET. Biochim. Biophys. Acta 2005, 1746, 45-54.
75. Hook, S. S.; Means, A. R. Ca(2+)/CaM-dependent kinases: From activation to function. Annu.Rev. Pharmacol. Toxicol. 2001, 41, 471-505.
76. Dzhura, I.; Wu, Y.; Colbran, R. J.; Balser, J. R.; Anderson, M. E. Calmodulin kinase determinescalcium-dependent facilitation of L-type calcium channels. Nat. Cell. Biol. 2000, 2, 173-177.
77. Maier, L. S.; Bers, D. M. Calcium, calmodulin, and calcium-calmodulin kinase II: Heartbeat toheartbeat and beyond. J. Mol. Cell. Cardiol. 2002, 34, 919-939.
78. Hain, J.; Onoue, H.; Mayrleitner, M.; Fleischer, S.; Schindler, H. Phosphorylation modulates thefunction of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J. Biol.Chem. 1995, 270, 2074-2081.
79. Sun, P.; Enslen, H.; Myung, P. S.; Maurer, R. A., Differential activation of CREB byCa2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a sitethat negatively regulates activity. Genes Dev. 1994, 8, 2527-2539.
80. Kolodziej, S. J.; Hudmon, A.; Waxham, M. N.; Stoops, J. K. Three-dimensional reconstructionsof calcium/calmodulin-dependent (CaM) kinase II-alpha and truncated CaM kinase II-alphareveal a unique organization for its structural core and functional domains. J. Biol. Chem. 2000,275, 14354-14359.
81. Gaertner, T. R.; Kolodziej, S. J.; Wang, D.; Kobayashi, R.; Koomen, J. M.; Stoops, J. K.;Waxham, M. N. Comparative analyses of the three-dimensional structures and enzymaticproperties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin-dependent protein kinaseII. J. Biol. Chem. 2004, 279, 12484-12494.
82. Kanaseki, T.; Ikeuchi, Y.; Sugiura, H.; Yamauchi, T. Structural features of Ca2+/calmodulindependentprotein kinase II revealed by electron microscopy. J. Cell. Biol. 1991, 115,1049-1060.
83. Palomeque, J.; Rueda, O. V.; Sapia, L.; Valverde, C. A.; Salas, M.; Petroff, M. V.; Mattiazzi, A.Angiotensin II-induced oxidative stress resets the Ca2+ dependence of Ca2+-calmodulin proteinkinase II and promotes a death pathway conserved across different species. Circ. Res. 2009, 105,1204-1212.
84. Xie, L. H.; Chen, F.; Karagueuzian, H. S.; Weiss, J. N. Oxidative-stress-inducedafterdepolarizations and calmodulin kinase II signaling. Circ. Res. 2009, 104, 79-86.
85. Maier, L. S.; Bers, D. M. Role of Ca2+/calmodulin-dependent protein kinase (CaMK) inexcitation-contraction coupling in the heart. Cardiovasc. Res. 2007, 73, 631-640.
86. Wu, Y.; Temple, J.; Zhang, R.; Dzhura, I.; Zhang, W.; Trimble, R.; Roden, D. M.; Passier, R.;Olson, E. N.; Colbran, R. J.; Anderson, M. E. Calmodulin kinase II and arrhythmias in a mousemodel of cardiac hypertrophy. Circulation 2002, 106, 1288-1293.
87. Sag, C. M.; Wadsack, D. P.; Khabbazzadeh, S.; Abesser, M.; Grefe, C.; Neumann, K.; Opiela, M.K.; Backs, J.; Olson, E. N.; Brown, J. H.; Neef, S.; Maier, S. K.; Maier, L. S.Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heartfailure. Circ. Heart Fail. 2009, 2, 664-675.
88. Yurukova, S.; Kilic, A.; Volker, K.; Leineweber, K.; Dybkova, N.; Maier, L. S.; Brodde, O. E.;Kuhn, M. CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation inANP-receptor deficient mice. Cardiovasc. Res. 2007, 73, 678-688.
89. Chelu, M. G.; Sarma, S.; Sood, S.; Wang, S.; van Oort, R. J.; Skapura, D. G.; Li, N.; Santonastasi, M.; Müller, F. U.; Schmitz, W.; Schotten, U.; Anderson, M. E.; Valderrábano, M.; Dobrev, D.;Wehrens, X.H. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrialfibrillation in mice. J. Clin. Invest. 2009, 119, 1940-1951.
90. Saito, T.; Fukuzawa, J.; Osaki, J.; Sakuragi, H.; Yao, N.; Haneda, T.; Fujino, T.; Wakamiya, N.;Kikuchi, K.; Hasebe, N. Roles of calcineurin and calcium/calmodulin-dependent protein kinaseII in pressure overload-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 2003, 35, 1153-1160.
91. Backs; J.; Backs, T.; Neef, S.; Kreusser, M. M.; Lehmann, L. H.; Patrick, D. M. Grueter, C.E. Richardson, J. A.; Hill, J. A.; Katus, H. A.; Bassel-Duby, R.; Maier, L. S.; Olson, E. N. Thedelta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodelingafter pressure overload. Proc. Natl. Acad. Sci. USA. 2009, 106, 2342-2347.
92. Colomer, J. M.; Mao, L.; Rockman, H. A.; Means, A. R. Pressure overload selectively upregulatesCa2+/calmodulin-dependent protein kinase II in vivo. Mol. Endocrinol. 2003, 17,183-192.
93. Peng, W.; Zhang, Y.; Zheng, M.; Cheng, H.; Zhu, W.; Cao, C. M.; Xiao, R. P. Cardioprotectionby CaMKII-deltaB is mediated by phosphorylation of heat shock factor 1 and subsequentexpression of inducible heat shock protein 70. Circ. Res. 2010, 106, 102-110.
94. Srinivasan, M.; Edman, C. F.; Schulman, H. Alternative splicing introduces a nuclearlocalization signal that targets multifunctional CaM kinase to the nucleus. J. Cell. Biol. 1994,126, 839-852.
95. Kohlhaas, M.; Zhang, T.; Seidler, T.; Zibrova, D.; Dybkova, N.; Steen, A.; Wagner, S.; Chen, L.;Brown, J. H.; Bers, D. M.; Maier, L. S. Increased sarcoplasmic reticulum calcium leak butunaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ. Res. 2006, 98, 235-244.
96. Kashiwase, K.; Higuchi, Y.; Hirotani, S.; Yamaguchi, O.; Hikoso, S.; Takeda, T.; Watanabe, T.;Taniike, M.; Nakai, A.; Tsujimoto, I.; Matsumura, Y.; Ueno, H.; Nishida, K.; Hori, M.; Otsu, K.CaMKII activates ASK1 and NF-kappaB to induce cardiomyocyte hypertrophy. Biochem.Biophys. Res. Commun. 2005, 327, 136-142.
97. Passier, R.; Zeng, H.; Frey, N.; Naya, F. J.; Nicol, R. L.; McKinsey, T. A.; Overbeek, P.;Richardson, J. A.; Grant, S. R.; Olson, E. N. Ca M. kinase signaling induces cardiac hypertrophyand activates the MEF2 transcription factor in vivo. J. Clin. Invest. 2000, 105, 1395-1406.
98. Woischwill, C.; Karczewski, P.; Bartsch, H.; Luther, H. P.; Kott, M.; Haase, H.; Morano, I.Regulation of the human atrial myosin light chain 1 promoter by Ca2+-calmodulin-dependentsignaling pathways. FASEB J. 2005, 19, 503-511.
99. Benter, I. F.; Juggi, J. S.; Khan, I.; Yousif, M. H.; Canatan, H.; Akhtar, S. Signal transductionmechanisms involved in cardiac preconditioning: Role of Ras-GTPase, Ca2+/calmodulindependentprotein kinase II and epidermal growth factor receptor. Mol. Cell. Biochem. 2005,268, 175-183.
100. Osada, M.; Netticadan, T.; Kawabata, K.; Tamura, K.; Dhalla, N. S. Ischemic preconditioningprevents I/R-induced alterations in SR calcium-calmodulin protein kinase II. Am. J. Physiol.Heart Circ. Physiol. 2000, 278, H1791-1798.
101. Netticadan, T.; Temsah, R. M.; Kawabata, K.; Dhalla, N. S. Sarcoplasmic reticulum Ca(2+)/Calmodulin-dependent protein kinase is altered in heart failure. Circ. Res. 2000, 86, 596-605.
102. MacDonnell, S. M.; Weisser-Thomas, J.; Kubo, H.; Hanscome, M.; Liu, Q.; Jaleel, N.; Berretta, R.; Chen, X.; Brown, J. H.; Sabri, A. K.; Molkentin, J. D.; Houser, S. R. CaMKII negativelyregulates calcineurin-NFAT signaling in cardiac myocytes. Circ. Res. 2009, 105, 316-325.
103. Nishizuka, Y. Studies and perspectives of protein kinase C. Science 1986, 233, 305-312.
104. Bogoyevitch, M. A.; Parker, P. J.; Sugden, P. H. Characterization of protein kinase C isotypeexpression in adult rat heart. Protein kinase C-epsilon is a major isotype present, and it isactivated by phorbol esters, epinephrine, and endothelin. Circ. Res. 1993, 72, 757-767.
105. Hambleton, M.; Hahn, H.; Pleger, S. T.; Kuhn, M. C.; Klevitsky, R.; Carr, A. N.; Kimball, T. F.;Hewett, T. E.; Dorn, G. W., 2nd; Koch, W. J.; Molkentin, J. D. Pharmacological- and genetherapy-based inhibition of protein kinase C-alpha/beta enhances cardiac contractility andattenuates heart failure. Circulation 2006, 114, 574-582.
106. Kraft, A. S.; Anderson, W. B. Phorbol esters increase the amount of Ca2+, phospholipiddependentprotein kinase associated with plasma membrane. Nature 1983, 301, 621-623.
107. Mellor, H.; Parker, P. J. The extended protein kinase C superfamily. Biochem. J. 1998, 332,281-292.
108. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of proteinkinase C. Science 1992, 258, 607-614.
109. Toker, A.; Newton, A. C. Cellular Signaling: Pivoting around PDK-1. Cell 2000, 103, 185-188.
110. Liu, X.; Wang, J.; Takeda, N.; Binaglia, L.; Panagia, V.; Dhalla, N. S. Changes in cardiac proteinkinase C activities and isozymes in streptozotocin-induced diabetes. Am. J. Physiol. Cell.Physiol. 1999, 277, E798-E804.
111. Gu, X.; Bishop, S. P. Increased protein kinase C and isozyme redistribution in pressure-overloadcardiac hypertrophy in the rat. Circ. Res. 1994, 75, 926-931.
112. Braun, M. U.; LaRosee, P.; Simonis, G.; Borst, M. M.; Strasser, R. H. Regulation of proteinkinase C isozymes in volume overload cardiac hypertrophy. Mol. Cell. Biochem. 2004, 262,135-143.
113. Paul, K.; Ball, N. A.; Dorn, G. W.; Walsh, R. A. Left ventricular stretch stimulatesangiotensin II-mediated phosphatidylinositol hydrolysis and protein kinase C epsilon isoformtranslocation in adult guinea pig hearts. Circ. Res. 1997, 81, 643-650.
114. Morgan, H. E.; Baker, K. M. Cardiac hypertrophy. Mechanical, neural, and endocrinedependence. Circulation 1991, 83, 13-25.
115. Komuro, I.; Katoh, Y.; Kaida, T.; Shibazaki, Y.; Kurabayashi, M.; Hoh, E.; Takaku, F.; Yazaki, Y. Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured ratcardiac myocytes. Possible role of protein kinase C activation. J. Biol. Chem. 1991, 266,1265-1268.
116. Sadoshima, J.; Jahn, L.; Takahashi, T.; Kulik, T. J.; Izumo, S. Molecular characterization of thestretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiachypertrophy. J. Biol. Chem. 1992, 267, 10551-10560.
117. Bayer, A. L.; Heidkamp, M. C.; Patel, N.; Porter, M.; Engman, S.; Samarel, A. M. Alterations inprotein kinase C isoenzyme expression and autophosphorylation during the progression ofpressure overload-induced left ventricular hypertrophy. Mol. Cell. Biochem. 2003, 242, 145-152.
118. Davidoff, A. J.; Davidson, M. B.; Carmody, M. W.; Davis, M. E.; Ren, J. Diabeticcardiomyocyte dysfunction and myocyte insulin resistance: Role of glucose-induced PKCactivity. Mol. Cell. Biochem. 2004, 262, 155-163.
119. Wang, M.; Zhang, W. B.; Zhu, J. H.; Fu, G. S.; Zhou, B. Q. Breviscapine ameliorates cardiacdysfunction and regulates the myocardial Ca(2+)-cycling proteins in streptozotocin-induceddiabetic rats. Acta Diabetol. 2009, doi:10.1007/s00592-009-0164-x.
120. Beckman, J. A.; Goldfine, A. B.; Gordon, M. B.; Garrett, L. A.; Creager, M. A. Inhibition ofprotein kinase C-beta prevents impaired endothelium-dependent vasodilation caused byhyperglycemia in humans. Circ. Res. 2002, 90, 107-111.
121. Braz, J. C.; Gregory, K.; Pathak, A.; Zhao, W.; Sahin, B.; Klevitsky, R.; Kimball, T. F.; Lorenz, J. N.; Nairn, A. C.; Liggett, S. B.; Bodi, I.; Wang, S.; Schwartz, A.; Lakatta, E. G.; DePaoli-Roach, A. A.; Robbins, J.; Hewett, T. E.; Bibb, J. A.; Westfall, M. V.; Kranias, E. G.; Molkentin, J. D. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nature Med.2004, 10, 248-254.
122. Hahn, H. S.; Marreez, Y.; Odley, A.; Sterbling, A.; Yussman, M. G.; Hilty, K. C.; Bodi, I.;Liggett, S. B.; Schwartz, A.; Dorn, G. W., Protein kinase Calpha negatively regulates systolicand diastolic function in pathological hypertrophy. Circ. Res. 2003, 93, 1111-1119.
123. Cotter, M. A.; Jack, A. M.; Cameron, N. E. Effects of the protein kinase C beta inhibitorLY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin.Sci. 2002, 103, 311-321.
124. Wu, Y.; Wu, G.; Qi, X.; Lin, H.; Qian, H.; Shen, J.; Lin, S. Protein kinase C beta inhibitorLY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1expression in the kidney in diabetic rats. J. Pharmacol. Sci. 2006, 101, 335-343.
125. Connelly, K. A.; Kelly, D. J.; Zhang, Y.; Prior, D. L.; Advani, A.; Cox, A. J.; Thai, K.; Krum, H.;Gilbert, R. E., Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function andreduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart Fail. 2009, 2,129-137.
126. Fujita, M.; Minamino, T.; Asanuma, H.; Sanada, S.; Hirata, A.; Wakeno, M.; Myoishi, M.;Okuda, H.; Ogai, A.; Okada, K.; Tsukamoto, O.; Koyama, H.; Hori, M.; Kitakaze, M.Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways inhypoperfused canine hearts. Hypertension 2005, 46, 113-117.
127. Boyle, A. J.; Kelly, D. J.; Zhang, Y.; Cox, A. J.; Gow, R. M.; Way, K.; Itescu, S.; Krum, H.;Gilbert, R. E. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunctionfollowing myocardial infarction. J. Mol. Cell. Cardiol. 2005, 39, 213-221.
128. Wang, J.; Liu, X.; Sentex, E.; Takeda, N.; Dhalla, N. S. Increased expression of protein kinase Cisoforms in heart failure due to myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2003,284, 2277-2287.
129. Liu, Q.; Chen, X.; Macdonnell, S. M.; Kranias, E. G.; Lorenz, J. N.; Leitges, M.; Houser, S. R.;Molkentin, J. D., Protein kinase Cα, but not PKCβ or PKCγ, regulates contractility and heartfailure susceptibility: Implications for ruboxistaurin as a novel therapeutic approach. Circ. Res.2009, 105, 194-200.
130. Young, L. H.; Balin, B. J.; Weis, M. T. Go 6983: a fast acting protein kinase C inhibitor thatattenuates myocardial ischemia/reperfusion injury. Cardiovasc. Drug Rev. 2005, 23, 255-272.
131. Peterman, E. E.; Taormina, P., II; Harvey, M.; Young, L. H. Go 6983 exerts cardioprotectiveeffects in myocardial ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2004, 43, 645-656.
132. Omiyi, D.; Brue, R. J.; Taormina, P., II; Harvey, M.; Atkinson, N.; Young, L. H., Protein kinaseC βII peptide inhibitor exerts cardioprotective effects in rat cardiac ischemia/reperfusion injury.J. Pharmacol. Exp. Ther. 2005, 314, 542-551.
133. Phillipson, A.; Peterman, E. E.; Taormina, P., Jr.; Harvey, M.; Brue, R. J.; Atkinson, N.; Omiyi, D.; Chukwu, U.; Young, L. H. Protein kinase C-inhibition exerts cardioprotective effects inischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H898-H907.
134. Hahn, H. S.; Yussman, M. G.; Toyokawa, T.; Marreez, Y.; Barrett, T. J.; Hilty, K. C.; Osinska, H.; Robbins, J.; Dorn, G. W. Ischemic protection and myofibrillar cardiomyopathy: Dosedependenteffects of in vivo delta-PKC inhibition. Circ. Res. 2002, 91, 741-748.
135. Fantinelli, J. C.; Mosca, S. M. Comparative effects of ischemic pre and postconditioning onischemia-reperfusion injury in spontaneously hypertensive rats (SHR). Mol. Cell. Biochem. 2007,296, 45-51.
136. Cave, A. C.; Apstein, C. S. Polymyxin B, a protein kinase C inhibitor, abolishes preconditioninginducedprotection against contractile dysfunction in the isolated blood perfused rat heart. J. Mol. Cell. Cardiol. 1996, 28, 977-987.
137. Liu, Y.; Tsuchida, A.; Cohen, M. V.; Downey, J. M. Pretreatment with angiotensin II activatesprotein kinase C and limits myocardial infarction in isolated rabbit hearts. J. Mol. Cell. Cardiol.1995, 27, 883-892.
138. Mochly-Rosen, D.; Wu, G.; Hahn, H.; Osinska, H.; Liron, T.; Lorenz, J. N.; Yatani, A.; Robbins, J.; Dorn, G. W. Cardiotrophic effects of protein kinase C epsilon: Analysis by in vivomodulation of PKCepsilon translocation. Circ. Res. 2000, 86, 1173-1179.
139. Ping, P.; Takano, H.; Zhang, J.; Tang, X. L.; Qiu, Y.; Li, R. C.; Banerjee, S.; Dawn, B.;Balafonova, Z.; Bolli, R. Isoform-selective activation of protein kinase C by nitric oxide in theheart of conscious rabbits: A signaling mechanism for both nitric oxide-induced and ischemiainducedpreconditioning. Circ. Res. 1999, 84, 587-604.
140. Inagaki, K.; Hahn, H. S.; Dorn, G. W.; Mochly-Rosen, D. Additive protection of theischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and epsilonproteinkinase C activator. Circulation 2003, 108, 869-875.
141. Teng, J. C.; Kay, H.; Chen, Q.; Adams, J. S.; Grilli, C.; Guglielmello, G.; Zambrano, C.; Krass, S.; Bell, A.; Young, L. H. Mechanisms related to the cardioprotective effects of protein kinase Cepsilon (PKC epsilon) peptide activator or inhibitor in rat ischemia/reperfusion injury. NaunynSchmiedebergs Arch. Pharmacol. 2008, 378, 1-15.
142. Yu, Q.; Nguyen, T.; Ogbi, M.; Caldwell, R. W.; Johnson, J. A. Differential loss of cytochrome-coxidase subunits in ischemia-reperfusion injury: Exacerbation of COI subunit loss by PKCepsiloninhibition. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H2637-2645.
143. Wang, G. Y.; Zhou, J. J.; Shan, J.; Wong, T. M. Protein kinase C-epsilon is a trigger of delayedcardioprotection against myocardial ischemia of κ-opioid receptor stimulation in rat ventricularmyocytes. J. Pharmacol. Exp. Ther. 2001, 299, 603-610.
144. Malhotra, A.; Kang, B. P.; Hashmi, S.; Meggs, L. G. PKC-epsilon inhibits the hyperglycemiainducedapoptosis signal in adult rat ventricular myocytes. Mol. Cell. Biochem. 2005, 268,169-173.
145. Malhotra, A.; Begley, R.; Kang, B. P.; Rana, I.; Liu, J.; Yang, G.; Mochly-Rosen, D.; Meggs, L.G. PKC-ε-dependent survival signals in diabetic hearts. Am. J. Physiol. Heart Circ. Physiol.2005, 289, H1343-H1350.
146. House, S. L.; Melhorn, S. J.; Newman, G.; Doetschman, T.; Schultz Jel, J. The protein kinase Cpathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblastgrowth factor-2. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H354-H365.
147. Das, A.; Ockaili, R.; Salloum, F.; Kukreja, R. C. Protein kinase C plays an essential role insildenafil-induced cardioprotection in rabbits. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1455-H1460.
148. Chen, L.; Hahn, H.; Wu, G.; Chen, C. H.; Liron, T.; Schechtman, D.; Cavallaro, G.; Banci, L.;Guo, Y.; Bolli, R.; Dorn, G. W., Mochly-Rosen, D. Opposing cardioprotective actions andparallel hypertrophic effects of δPKC and εPKC. Proc. Natl. Acad. Sci. USA. 2001, 98,11114-11119.
149. Carpenter, C. L.; Duckworth, B. C.; Auger, K. R.; Cohen, B.; Schaffhausen, B. S.; Cantley, L. C.Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem.1990, 265, 19704-19711.
150. Escobedo, J. A.; Navankasattusas, S.; Kavanaugh, W. M.; Milfay, D.; Fried, V. A.; Williams, L.T. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF β-receptor. Cell 1991, 65, 75-82.
151. Otsu, M.; Hiles, I.; Gout, I.; Fry, M. J.; Ruiz-Larrea, F.; Panayotou, G.; Thompson, A.; Dhand, R.; Hsuan, J.; Totty, N.; et al. Characterization of two 85 kd proteins that associate with receptortyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 1991, 65, 91-104.
152. Skolnik, E. Y.; Margolis, B.; Mohammadi, M.; Lowenstein, E.; Fischer, R.; Drepps, A.; Ullrich, A.; Schlessinger, J. Cloning of PI3 kinase-associated p85 utilizing a novel method forexpression/cloning of target proteins for receptor tyrosine kinases. Cell 1991, 65, 83-90.
153. Geering, B.; Cutillas, P. R.; Nock, G.; Gharbi, S. I.; Vanhaesebroeck, B. Class IAphosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. USA 2007, 104, 7809-7814.
154. Walker, E. H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R. L. Structural insights intophosphoinositide 3-kinase catalysis and signaling. Nature 1999, 402, 313-320.
155. Williams, R.; Berndt, A.; Miller, S.; Hon, W. C.; Zhang, X. Form and flexibility inphosphoinositide 3-kinases. Biochem. Soc. Trans. 2009, 37, 615-626.
156. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.;Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K.M. A pharmacological map of the PI3-K family defines a role for p110-α in insulin signaling.Cell 2006, 125, 733-747.
157. Crackower, M. A.; Oudit, G. Y.; Kozieradzki, I.; Sarao, R.; Sun, H.; Sasaki, T.; Hirsch, E.; Suzuki, A.; Shioi, T.; Irie-Sasaki, J.; Sah, R.; Cheng, H. Y.; Rybin, V. O.; Lembo, G.; Fratta, L.;Oliveira-dos-Santos, A. J.; Benovic, J. L.; Kahn, C. R.; Izumo, S.; Steinberg, S. F.; Wymann, M.P.; Backx, P. H.; Penninger, J. M. Regulation of myocardial contractility and cell size by distinctPI3K-PTEN signaling pathways. Cell 2002, 110, 737-749.
158. Rose, R. A.; Kabir, M. G.; Backx, P. H. Altered heart rate and sinoatrial node function in micelacking the cAMP regulator phosphoinositide 3-kinase-γ. Circ. Res. 2007, 101, 1274-1282.
159. Ravingerova, T.; Matejikova, J.; Neckar, J.; Andelova, E.; Kolar, F. Differential role ofPI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart.Mol. Cell. Biochem. 2007, 297, 111-120.
160. Siragusa, M.; Katare, R.; Meloni, M.; Damilano, F.; Hirsch, E.; Emanueli, C.; Madeddu, P.Involvement of phosphoinositide 3-kinase γ in angiogenesis and healing of experimentalmyocardial infarction in mice. Circ. Res. 2010, 106, 757-768.
161. Perrino, C.; Rockman, H. A.; Chiariello, M. Targeted inhibition of phosphoinositide 3-kinaseactivity as a novel strategy to normalize β-adrenergic receptor function in heart failure. Vascul.Pharmacol. 2006, 45, 77-85.
162. Perrino, C.; Naga Prasad, S. V.; Patel, M.; Wolf, M. J.; Rockman, H. A. Targeted inhibition of β-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves β-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrinoverexpression. J. Am. Coll. Cardiol. 2005, 45, 1862-1870.
163. Perrino, C.; Naga Prasad, S. V.; Schroder, J. N.; Hata, J. A.; Milano, C.; Rockman, H. A.Restoration of β-adrenergic receptor signaling and contractile function in heart failure bydisruption of the β-ARK1/phosphoinositide 3-kinase complex. Circulation 2005, 111,2579-2587.
164. Nienaber, J. J.; Tachibana, H.; Naga Prasad, S. V.; Esposito, G.; Wu, D.; Mao, L.; Rockman, H.A. Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function andameliorates pressure overload heart failure. J. Clin. Invest. 2003, 112, 1067-1079.
165. Awad, A. E.; Kandalam, V.; Chakrabarti, S.; Wang, X.; Penninger, J. M.; Davidge, S. T.; Oudit, G. Y.; Kassiri, Z. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytesand cardiofibroblasts differentially via superoxide production in a PI3K-gamma-dependentmanner. Am. J. Physiol. Cell. Physiol 2010, 298, 679-692.
166. Perrino, C.; Naga Prasad, S. V.; Mao, L.; Noma, T.; Yan, Z.; Kim, H. S.; Smithies, O.; Rockman, H. A. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction andvascular rarefaction. J. Clin. Invest. 2006, 116, 1547-1560.
167. Luo, J.; McMullen, J. R.; Sobkiw, C. L.; Zhang, L.; Dorfman, A. L.; Sherwood, M. C.; Logsdon, M. N.; Horner, J. W.; dePinho, R. A.; Izumo, S.; Cantley, L. C. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 2005, 25,9491-9502.
168. Deschamps, A. M.; Murphy, E. Activation of a novel estrogen receptor, GPER, iscardioprotective in male and female rats. Am. J. Physiol. Heart Circ. Physiol. 2009, 297,1806-1813.
169. Chaudhary, K. R.; Batchu, S. N.; Das, D.; Suresh, M. R.; Falck, J. R.; Graves, J. P.; Zeldin, D.C.; Seubert, J. M. Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediatedimproved post-ischaemic recovery of heart contractile function. Cardiovasc. Res. 2009, 83,362-370.
170. Okumura, H.; Nagaya, N.; Itoh, T.; Okano, I.; Hino, J.; Mori, K.; Tsukamoto, Y.; Ishibashi-Ueda, H.; Miwa, S.; Tambara, K.; Toyokuni, S.; Yutani, C.; Kangawa, K. Adrenomedullininfusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004, 109, 242-248.
171. Pretorius, L.; Du, X. J.; Woodcock, E. A.; Kiriazis, H.; Lin, R. C.; Marasco, S.; Medcalf, R. L.;Ming, Z.; Head, G. A.; Tan, J. W.; Cemerlang, N.; Sadoshima, J.; Shioi, T.; Izumo, S.;Lukoshkova, E. V.; Dart, A. M.; Jennings, G. L.; McMullen, J. R. Reduced phosphoinositide 3-kinase (p110-α) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 2009,175, 998-1009.
172. Lu, Z.; Jiang, Y. P.; Wang, W.; Xu, X. H.; Mathias, R. T.; Entcheva, E.; Ballou, L. M.; Cohen, I.S.; Lin, R. Z. Loss of cardiac phosphoinositide 3-kinase p110 α results in contractile dysfunction.Circulation 2009, 120, 318-325.
173. McMullen, J. R.; Amirahmadi, F.; Woodcock, E. A.; Schinke-Braun, M.; Bouwman, R. D.;Hewitt, K. A.; Mollica, J. P.; Zhang, L.; Zhang, Y.; Shioi, T.; Buerger, A.; Izumo, S.; Jay, P. Y.;Jennings, G. L. Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling indilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 2007, 104, 612-617.
174. McMullen, J. R.; Shioi, T.; Zhang, L.; Tarnavski, O.; Sherwood, M. C.; Kang, P. M.; Izumo, S.Phosphoinositide 3-kinase(p110-α) plays a critical role for the induction of physiological, but notpathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2003, 100, 12355-12360.
175. Takenaka, H.; Horiba, M.; Ishiguro, H.; Sumida, A.; Hojo, M.; Usui, A.; Akita, T.; Sakuma, S.;Ueda, Y.; Kodama, I.; Kadomatsu, K. Midkine prevents ventricular remodeling and improveslong-term survival after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2009, 296,462-469.
176. Mao, W.; Iwai, C.; Liu, J.; Sheu, S. S.; Fu, M.; Liang, C. S. Darbepoetin alfa exerts acardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activationof the PI3K/Akt and STAT3 pathways. J. Mol. Cell. Cardiol. 2008, 45, 250-260.
177. Curcio, A.; Noma, T.; Naga Prasad, S. V.; Wolf, M. J.; Lemaire, A.; Perrino, C.; Mao, L.;Rockman, H. A. Competitive displacement of phosphoinositide 3-kinase from β-adrenergicreceptor kinase-1 improves postinfarction adverse myocardial remodeling. Am. J. Physiol. HeartCirc. Physiol. 2006, 291, H1754-H1760.
178. Wang, W.; Peng, Y.; Wang, Y.; Zhao, X.; Yuan, Z. The anti-apoptotic effect of heat shockprotein 90 on hypoxia-mediated cardiomyocyte damage through the Pi3k/Akt pathway. Clin.Exp. Pharmacol. Physiol. 2009.
179. Wang, M. J.; Wang, Y.; Weil, B.; Abarbanell, A.; Herrmann, J.; Tan, J. N.; Kelly, M.; Meldrum, D. R. Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improvedmyocardial function in female hearts following acute ischemia. Am. J. Physiol. Regul. Integr. Compar. Physiol. 2009, 296, R972-R978.
180. Bulhak, A. A.; Jung, C.; Ostenson, C. G.; Lundberg, J. O.; Sjoquist, P. O.; Pernow, J. PPAR-αactivation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: Involvement of the PI3-Kinase/Akt and NO pathway. Am. J. Physiol. Heart Circ. Physiol. 2009,296, H719-727.
181. Tsang, A.; Hausenloy, D. J.; Mocanu, M. M.; Carr, R. D.; Yellon, D. M. Preconditioning thediabetic heart: The importance of Akt phosphorylation. Diabetes 2005, 54, 2360-2364.
182. Baines, C. P.; Wang, L.; Cohen, M. V.; Downey, J. M. Myocardial protection by insulin isdependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in theisolated rabbit heart. Basic Res. Cardiol. 1999, 94, 188-198.
183. Kim, K. H.; Oudit, G. Y.; Backx, P. H. Erythropoietin protects against doxorubicin-inducedcardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J. Pharmacol. Exp.Ther. 2008, 324, 160-169.
184. Hu, Y.; Chen, X.; Pan, T. T.; Neo, K. L.; Lee, S. W.; Khin, E. S.; Moore, P. K.; Bian, J. S.Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK andPI3K/Akt pathways. Pflugers Arch. 2008, 455, 607-616.
185. Nagoshi, T.; Matsui, T.; Aoyama, T.; Leri, A.; Anversa, P.; Li, L.; Ogawa, W.; del Monte, F.;Gwathmey, J. K.; Grazette, L.; Hemmings, B. A.; Kass, D. A.; Champion, H. C.; Rosenzweig, A.PI3K rescues the detrimental effects of chronic Akt activation in the heart duringischemia/reperfusion injury. J. Clin. Invest. 2005, 115, 2128-2138.
186. Chiari, P. C.; Bienengraeber, M. W.; Pagel, P. S.; Krolikowski, J. G.; Kersten, J. R.; Warltier, D.C. Isoflurane protects against myocardial infarction during early reperfusion by activation ofphosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-inducedpostconditioning in rabbits. Anesthesiology 2005, 102, 102-109.
187. Tsang, A.; Hausenloy, D. J.; Mocanu, M. M.; Yellon, D. M. Postconditioning: A form ofmodified reperfusion protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res. 2004, 95, 230-232.
188. Tang, J.; Wang, J.; Kong, X.; Yang, J.; Guo, L.; Zheng, F.; Zhang, L.; Huang, Y.; Wan, Y.Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Aktpathway. Exp. Cell Res. 2009, 315, 3521-3531.
189. Chan, T. O.; Rittenhouse, S. E.; Tsichlis, P. N. AKT/PKB and other D3 phosphoinositideregulatedkinases: Kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem. 1999, 68, 965-1014.
190. DeBosch, B.; Treskov, I.; Lupu, T. S; Weinheimer, C.; Kovacs, A.; Courtois, M.; Muslin, A. J. Akt1 is required for physiological cardiac growth. Circulation 2006, 113, 2097-2104.
191. DeBosch, B.; Sambandam, N.; Weinheimer, C.; Courtois, M.; Muslin, A. J. Akt2 regulatescardiac metabolism and cardiomyocyte survival. J. Biol. Chem. 2006, 281, 32841-32851.
192. Schindler, J. F.; Monahan, J. B.; Smith, W. G. p38 pathway kinases as anti-inflammatory drugtargets. J. Dent. Res. 2007, 86, 800-811.
193. Xu, Y. J.; Saini, H. K.; Zhang, M.; Elimban, V.; Dhalla, N. S. MAPK activation and apoptoticalterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc. Res.2006, 72, 163-174.
194. Wang, Y.; Huang, S.; Sah, V. P.; Ross, J., Jr.; Brown, J. H.; Han, J.; Chien, K. R. Cardiac musclecell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated proteinkinase family. J. Biol. Chem. 1998, 273, 2161-2168.
195. See, F.; Thomas, W.; Way, K.; Tzanidis, A.; Kompa, A.; Lewis, D.; Itescu, S.; Krum, H. p38mitogen-activated protein kinase inhibition improves cardiac function and attenuates leftventricular remodeling following myocardial infarction in the rat. J. Am. Coll. Cardiol. 2004, 44,1679-1689.
196. Barancik, M.; Htun, P.; Strohm, C.; Kilian, S.; Schaper, W. Inhibition of the cardiac p38-MAPKpathway by SB203580 delays ischemic cell death. J. Cardiovasc. Pharmacol. 2000, 35, 474-483.
197. Pombo, C. M.; Bonventre, J. V.; Avruch, J.; Woodgett, J. R.; Kyriakis, J. M.; Force, T. Thestress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemiaand reperfusion. J. Biol. Chem. 1994, 269, 26546-26551.
198. Nagarkatti, D. S.; Sha'afi, R. I. Role of p38 MAP kinase in myocardial stress. J. Mol. Cell.Cardiol. 1998, 30, 1651-1664.
199. Saurin, A. T.; Martin, J. L.; Heads, R. J.; Foley, C.; Mockridge, J. W.; Wright, M. J.; Wang, Y.;Marber, M. S. The role of differential activation of p38-mitogen-activated protein kinase inpreconditioned ventricular myocytes. FASEB J. 2000, 14, 2237-2246.
200. Ma, X. L.; Kumar, S.; Gao, F.; Louden, C. S.; Lopez, B. L.; Christopher, T. A.; Wang, C.; Lee, J.C.; Feuerstein, G. Z.; Yue, T. L. Inhibition of p38 mitogen-activated protein kinase decreasescardiomyocyte apoptosis and improves cardiac function after myocardial ischemia andreperfusion. Circulation 1999, 99, 1685-1691.
201. Mackay, K.; Mochly-Rosen, D. An inhibitor of p38 mitogen-activated protein kinase protectsneonatal cardiac myocytes from ischemia. J. Biol. Chem. 1999, 274, 6272-6279.
202. Martin, J. L.; Avkiran, M.; Quinlan, R. A.; Cohen, P.; Marber, M. S. Antiischemic effects ofSB203580 are mediated through the inhibition of p38-α mitogen-activated protein kinase:Evidence from ectopic expression of an inhibition-resistant kinase. Circ. Res. 2001, 89, 750-752.
203. Otsu, K.; Yamashita, N.; Nishida, K.; Hirotani, S.; Yamaguchi, O.; Watanabe, T.; Hikoso, S.;Higuchi, Y.; Matsumura, Y.; Maruyama, M.; Sudo, T.; Osada, H.; Hori, M. Disruption of asingle copy of the p38-α MAP kinase gene leads to cardioprotection against ischemiareperfusion.Biochem. Biophys. Res. Commun. 2003, 302, 56-60.
204. Willette, R. N.; Eybye, M. E.; Olzinski, A. R.; Behm, D. J.; Aiyar, N.; Maniscalco, K.; Bentley, R. G.; Coatney, R. W.; Zhao, S.; Westfall, T. D.; Doe, C. P. Differential effects of p38 mitogenactivatedprotein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J.Pharmacol. Exp. Ther. 2009, 330, 964-970.
205. Shi, J.; Guan, J.; Jiang, B.; Brenner, D. A.; Del Monte, F.; Ward, J. E.; Connors, L. H.; Sawyer, D. B.; Semigran, M. J.; Macgillivray, T. E.; Seldin, D. C.; Falk, R.; Liao, R. Amyloidogenic lightchains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38-αMAPK pathway. Proc. Natl. Acad. Sci. USA 2010, 107, 4188-4193.
206. Yin, H.; Zhang, J.; Lin, H.; Wang, R.; Qiao, Y.; Wang, B.; Liu, F. p38 mitogen-activated proteinkinase inhibition decreases TNF-α secretion and protects against left ventricular remodeling inrats with myocardial ischemia. Inflammation 2008, 31, 65-73.
207. Liu, Z.; Cao, W. p38 mitogen-activated protein kinase: A critical node linking insulin resistanceand cardiovascular diseases in type 2 diabetes mellitus. Endocr. Metab. Immune Disord. Drug Targets 2009, 9, 38-46.
208. Wenzel, S.; Soltanpour, G.; Schluter, K. D. No correlation between the p38 MAPK pathway andthe contractile dysfunction in diabetic cardiomyocytes: Hyperglycaemia-induced signaling andcontractile function. Pflugers Arch. 2005, 451, 328-337.
209. Ogut, O.; Brozovich, F. V. The potential role of MLC phosphatase and MAPK signaling in thepathogenesis of vascular dysfunction in heart failure. J. Cell. Mol. Med. 2008, 12, 2158-2164.
210. Fan, L.; Sawbridge, D.; George, V.; Teng, L.; Bailey, A.; Kitchen, I.; Li, J. M. Chronic cocaineinducedcardiac oxidative stress and mitogen-activated protein kinase activation: The role ofNox2 oxidase. J. Pharmacol. Exp. Ther. 2009, 328, 99-106.
211. Muslin, A. J. Mapk signaling in cardiovascular health and disease: Molecular mechanisms andtherapeutic targets. Clin. Sci. 2008, 115, 203-218.
212. Bao, W.; Behm, D. J.; Nerurkar, S. S.; Ao, Z.; Bentley, R.; Mirabile, R. C.; Johns, D. G.; Woods, T. N.; Doe, C. P.; Coatney, R. W.; Ohlstein, J. F.; Douglas, S. A.; Willette, R. N.; Yue, T. L.Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, andsuperoxide anion production. J. Cardiovasc. Pharmacol. 2007, 49, 362-368.
213. Sato, H.; Tanaka, T.; Kasai, K.; Kita, T.; Tanaka, N. Role of p38 mitogen-activated proteinkinase on cardiac dysfunction after hemorrhagic shock in rats. Shock 2007, 28, 291-299.
214. Westermann, D.; Rutschow, S.; Van Linthout, S.; Linderer, A.; Bucker-Gartner, C.; Sobirey, M.;Riad, A.; Pauschinger, M.; Schultheiss, H. P.; Tschope, C. Inhibition of p38 mitogen-activatedprotein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiaccytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006, 49, 2507-2513.
215. Kyoi, S.; Otani, H.; Matsuhisa, S.; Akita, Y.; Tatsumi, K.; Enoki, C.; Fujiwara, H.; Imamura, H.;Kamihata, H.; Iwasaka, T. Opposing effect of p38 MAP kinase and JNK inhibitors on thedevelopment of heart failure in the cardiomyopathic hamster. Cardiovasc. Res. 2006, 69,888-898.
216. Li, Z.; Ma, J. Y.; Kerr, I.; Chakravarty, S.; Dugar, S.; Schreiner, G.; Protter, A. A. Selectiveinhibition of p38-alpha MAPK improves cardiac function and reduces myocardial apoptosis inrat model of myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H1972-H1977.
217. Wang, M.; Sankula, R.; Tsai, B. M.; Meldrum, K. K.; Turrentine, M.; March, K. L.; Brown, J.W.; Dinarello, C. A.; Meldrum, D. R. P38 MAPK mediates myocardial proinflammatorycytokine production and endotoxin-induced contractile suppression. Shock 2004, 21, 170-174.
218. Peng, T.; Lu, X.; Lei, M.; Moe, G. W.; Feng, Q. Inhibition of p38 MAPK decreases myocardialTNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc. Res. 2003, 59, 893-900.
219. Cain, B. S.; Meldrum, D. R.; Meng, X.; Dinarello, C. A.; Shames, B. D.; Banerjee, A.; Harken, A. H. p38 MAPK inhibition decreases TNF-α production and enhances postischemic humanmyocardial function. J. Surg. Res. 1999, 83, 7-12.
220. Li, G.; Ali, I. S.; Currie, R. W. Insulin-induced myocardial protection in isolated ischemic rathearts requires p38 MAPK phosphorylation of Hsp27. Am. J. Physiol. Heart Circ. Physiol. 2008,294, H74-H87.
221. Yoshimura, Y.; Kristo, G.; Keith, B. J.; Jahania, S. A.; Mentzer, R. M., Jr.; Lasley, R. D. The p38MAPK inhibitor SB203580 blocks adenosine A(1) receptor-induced attenuation of in vivomyocardial stunning. Cardiovasc. Drugs Ther. 2004, 18, 433-440.
222. Kristo, G.; Yoshimura, Y.; Keith, B. J.; Stevens, R. M.; Jahania, S. A.; Mentzer, R. M., Jr.; Lasley, R. D. Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayedpreconditioning against in vivo myocardial stunning. Am. J. Physiol. Heart Circ. Physiol. 2004,287, H2746-H2753.
223. Cameron, S. J.; Itoh, S.; Baines, C. P.; Zhang, C.; Ohta, S.; Che, W.; Glassman, M.; Lee, J. D.;Yan, C.; Yang, J.; Abe, J. Activation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injuryafter myocardial ischemia and reperfusion. FEBS Lett. 2004, 566, 255-260.
224. Yasaka, A.; Hayashida, W. Alterations of load-induced p38 MAP kinase activation in failing rathearts. Biochem. Biophys. Res. Commun. 2001, 285, 503-507.
225. Braz, J. C.; Bueno, O. F.; Liang, Q.; Wilkins, B. J.; Dai, Y. S.; Parsons, S.; Braunwart, J.;Glascock, B. J.; Klevitsky, R.; Kimball, T. F.; Hewett, T. E.; Molkentin, J. D. Targeted inhibitionof p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Invest. 2003, 111, 1475-1486.
226. Liu, J.; Sadoshima, J.; Zhai, P.; Hong, C.; Yang, G.; Chen, W.; Yan, L.; Wang, Y.; Vatner, S. F.;Vatner, D. E. Pressure overload induces greater hypertrophy and mortality in female mice withp38-α MAPK inhibition. J. Mol. Cell. Cardiol. 2006, 41, 680-688.
227. Mocanu, M. M.; Baxter, G. F.; Yue, Y.; Critz, S. D.; Yellon, D. M. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration iscritical. Basic. Res. Cardiol. 2000, 95, 472-478.
228. Iliodromitis, E. K.; Aggeli, I. K.; Gaitanaki, C.; Tsiafoutis, I.; Zoga, A.; Beis, I.; Kremastinos, D.T. p38-MAPK is involved in restoration of the lost protection of preconditioning by nicorandil invivo. Eur. J. Pharmacol. 2008, 579, 289-297.
229. Bell, J. R.; Eaton, P.; Shattock, M. J. Role of p38-mitogen-activated protein kinase in ischaemicpreconditioning in rat heart. Clin. Exp. Pharmacol. Physiol. 2008, 35, 126-134.
230. Jaswal, J. S.; Gandhi, M.; Finegan, B. A.; Dyck, J. R.; Clanachan, A. S. Inhibition of p38 MAPKand AMPK restores adenosine-induced cardioprotection in hearts stressed by antecedentischemia by altering glucose utilization. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H1107-H1114.
231. Wu, X.; Liu, X.; Zhu, X.; Tang, C. Hypoxic preconditioning induces delayed cardioprotectionthrough p38 MAPK-mediated calreticulin upregulation. Shock 2007, 27, 572-577.
232. Ruusalepp, A.; Czibik, G.; Flatebo, T.; Vaage, J.; Valen, G. Myocardial protection evoked byhyperoxic exposure involves signaling through nitric oxide and mitogen activated proteinkinases. Basic Res. Cardiol. 2007, 102, 318-326.
233. House, S. L.; Branch, K.; Newman, G.; Doetschman, T.; Schultz Jel, J. Cardioprotection inducedby cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPKcascade. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2167-H2175.
234. Liu, Y. H.; Wang, D.; Rhaleb, N. E.; Yang, X. P.; Xu, J.; Sankey, S. S.; Rudolph, A. E.;Carretero, O. A. Inhibition of p38 mitogen-activated protein kinase protects the heart againstcardiac remodeling in mice with heart failure resulting from myocardial infarction. J. Card. Fail.2005, 11, 74-81.
235. Weinbrenner, C.; Liu, G. S.; Cohen, M. V.; Downey, J. M. Phosphorylation of tyrosine 182 ofp38 mitogen-activated protein kinase correlates with the protection of preconditioning in therabbit heart. J. Mol. Cell. Cardiol. 1997, 29, 2383-2391.
236. Bogoyevitch, M. A.; Sugden, P. H. The role of protein kinases in adaptational growth of theheart. Int. J. Biochem. Cell Biol. 1996, 28, 1-12.
237. Malhotra, A.; Kang, B. P.; Opawumi, D.; Belizaire, W.; Meggs, L. G. Molecular biology ofprotein kinase C signaling in cardiac myocytes. Mol. Cell. Biochem. 2001, 225, 97-107.
238. Djordjevic, S.; Driscoll, P. C. Structural insight into substrate specificity and regulatorymechanisms of phosphoinositide 3-kinases. Trends Biochem. Sci. 2002, 27, 426-432.
239. Krishna, M.; Narang, H. The complexity of mitogen-activated protein kinases (MAPKs) madesimple. Cell. Mol. Life Sci. 2008, 65, 3525-3544.
240. Martindale, J. J.; Wall, J. A.; Martinez-Longoria, D. M.; Aryal, P.; Rockman, H. A.; Guo, Y.;Bolli, R.; Glembotski, C. C. Overexpression of mitogen-activated protein kinase kinase 6 in theheart improves functional recovery from ischemia in vitro and protects against myocardialinfarction in vivo. J. Biol. Chem. 2005, 280, 669-676.
241. Bassi, R.; Heads, R.; Marber, M. S.; Clark, J. E. Targeting p38-MAPK in the ischaemic heart:Kill or cure? Curr. Opin. Pharmacol. 2008, 8, 141-146.
242. Zhang, W.; Elimban, V.; Xu, Y. J.; Zhang, M.; Nijjar, M. S.; Dhalla, N. S. Alterations of cardiacERK1/2 expression and activity due to volume overload were attenuated by the blockade ofRAS. J. Cardiovasc. Pharmacol. Ther 2010, 15, 84-92.
243. Sharma, V.; Abraham, T.; So, A.; Allard, M. F.; McNeill, J. H. Functional effects of proteinkinases and peroxynitrite on cardiac carnitine palmitoyltransferase-1 in isolated mitochondria.Mol. Cell. Biochem. 2010, 337, 223-237.
244. Fryer, R. M.; Wang, Y.; Hsu, A. K.; Nagase, H.; Gross, G. J. Dependence of β1-opioid receptorinducedcardioprotection on a tyrosine kinase-dependent but not a Src-dependent pathway. J.Pharmacol. Exp. Ther. 2001, 299, 477-482.
245. Fryer, R. M.; Schultz, J. E.; Hsu, A. K.; Gross, G. J. Importance of PKC and tyrosine kinase insingle or multiple cycles of preconditioning in rat hearts. Am. J. Physiol. Cell. Physiol. 1999,276, H1229-H1235.
246. Okubo, S.; Tanabe, Y.; Takeda, K.; Kitayama, M.; Kanemitsu, S.; Kukreja, R. C.; Takekoshi, N.Pretreatment with tyrosine kinase inhibitor attenuates the reduction of apoptosis 24 h afterischemic preconditioning. Jpn. J. Physiol. 2004, 54, 143-151.